source
- GSK and Ionis receive FDA nod for Hibsago, a potential functional cure for chronic hepatitis BThe U.S. Food and Drug Administration has cleared Hibsago, a collaborative product of GSK and Ionis, as the first therapy of its kind aimed at chronic hepatitis B. The medicine is to be added to s…
- Disc Medicine’s Phase 3 data revives rejected rare‑disease drug as China tightens biotech ownership rulesDisc Medicine announced that its Phase 3 trial of a previously rejected rare‑disease therapy showed positive results, effectively rescuing the program and positioning it for another submission to t…